来特莫韦成功治疗一名心脏移植受者，该受者患有 UL97 突变的耐更昔洛韦巨细胞病毒结肠炎和病毒血症。
Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
作者信息
Yanase Tomonobu, Hatano Masaru, Bujo Chie, Tsuji Masaki, Ishida Junichi, Amiya Eisuke, Okamoto Koh, Ando Masahiko, Shimada Shogo, Kinoshita Osamu, Fukushi Shuetsu, Yamada Souichi, Ono Minoru, Komuro Issei
机构信息
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
Advanced Medical Center for Heart Failure, The University of Tokyo Hospital.
出版信息
Int Heart J. 2023 Mar 31;64(1):95-99. doi: 10.1536/ihj.22-496. Epub 2023 Jan 23.
Currently available anti-cytomegalovirus (CMV) agents are sometimes poorly tolerated, owing to their side effects. Letermovir is a novel anti-CMV drug that is only approved for CMV prophylaxis in hematopoietic stem cell transplant recipients, with fewer side effects. We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully treated with off-label use of letermovir. In treating CMV infection or disease with letermovir, a transient rise or lag in the clearance of CMV-DNA polymerase chain reaction levels has been observed. Our case suggests that CMV-pp65 antigenemia can be an additional marker of treatment efficacy.
目前可用的抗巨细胞病毒（CMV）药物有时耐受性较差，因为它们有副作用。来特莫韦是一种新型抗CMV药物，仅被批准用于造血干细胞移植受者的CMV预防，副作用较少。我们报告了一例心脏移植受者，其患有UL97突变（L595F）的耐更昔洛韦巨细胞病毒性结肠炎，通过来特莫韦的超说明书使用成功治愈。在用来特莫韦治疗CMV感染或疾病时，已观察到CMV-DNA聚合酶链反应水平的清除出现短暂上升或滞后。我们的病例表明，CMV-pp65抗原血症可以作为治疗效果的额外标志物。
Zotero 插件